EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer’s Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis

Chen Jiang, Josh Krivinko, Zeshui Yu, Robert A Sweet, Lang Zeng, Hui Wang, Ying Ding, Zheng Zeng, Julia Kofler, Lirong Wang iD

CNS Drugs · 2026-06 · 40 (6) · 823-833

DOI: 10.1007/s40263-026-01286-9 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift CNS Drugs, online erschienen am 28.03.2026. Verfasst von Chen Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 15261, USA. Hauptthemen laut MEDLINE: Antipsychotic Agents, Aripiprazole, Alzheimer Disease, Olanzapine. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIMH NIH HHS, National Institute of Mental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsAripiprazoleAlzheimer DiseaseOlanzapineQuetiapine FumarateRisperidoneHumansFemaleRetrospective StudiesMaleAgedTreatment Effect HeterogeneityAged, 80 and overCohort Studies

Substanzen

Antipsychotic AgentsAripiprazoleOlanzapineQuetiapine FumarateRisperidone

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 15261, USA.
  • Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Lumbrita LLC, Los Gatos, CA, USA.
  • Alzheimer Disease Research Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh, PA, USA.
  • Division of Neuropathology, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

ORCID-Profile: Lirong Wang

Förderung

  • NIA NIH HHS
  • NIMH NIH HHS
  • National Institute of Mental Health
  • National Institute on Aging

Zitieren

APA

Jiang, C., Krivinko, J., Yu, Z., Sweet, R. A., Zeng, L., Wang, H., Ding, Y., Zeng, Z., Kofler, J., & Wang, L. (2026). Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer’s Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis. CNS Drugs, 40(6), 823-833. https://doi.org/10.1007/s40263-026-01286-9

Vancouver

Jiang C, Krivinko J, Yu Z, Sweet RA, Zeng L, Wang H, et al. Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer’s Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis. CNS Drugs. 2026;40(6):823-833. doi:10.1007/s40263-026-01286-9

BibTeX
@article{Jiang2026,
  author = {Jiang, Chen and Krivinko, Josh and Yu, Zeshui and Sweet, Robert A and Zeng, Lang and Wang, Hui and Ding, Ying and Zeng, Zheng and Kofler, Julia and Wang, Lirong},
  title = {Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer’s Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis},
  journal = {CNS Drugs},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {823--833},
  doi = {10.1007/s40263-026-01286-9}
}
Kostenlos starten →